Skip to main content
Erschienen in: La radiologia medica 12/2016

01.12.2016 | ONCOLOGY IMAGING

Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy

verfasst von: Marco Tampellini, Dario Gned, Chiara Baratelli, Maria Pia Brizzi, Azzurra Ottone, Irene Alabiso, Chiara Bertaggia, Massimo Di Maio, Giorgio Vittorio Scagliotti, Andrea Veltri

Erschienen in: La radiologia medica | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Blood perfusion of liver metastases can be non-invasively assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The aim of this study was to explore whether the ratio of hepatic arterial to total liver blood flow (Hepatic Perfusion Index—HPI) and the area under the enhancement curve (AUC) of selected liver areas in patients with hepatic metastases from colorectal cancer treated with first-line chemotherapy could predict response and/or be a prognostic variable.

Patients and methods

Sequential liver DCE-MRI studies with morphological imaging reconstruction were performed in 43 consecutive patients at baseline and every 3 months during oxaliplatin-based first-line chemotherapy. Data about HPI of the whole liver, and AUC of metastatic and healthy areas were calculated at each time-point and compared both at baseline and sequentially during the treatment.

Results

Baseline HPI and AUC values did not discriminate patients responsive to chemotherapy, nor those with better survival outcomes. HPI and AUC values at 3 months decreased significantly more in responders than non-responders. AUCs calculated from areas of the liver with or without neoplastic lesions varied consistently, being increased in progressing patients and decreased in responding patients.

Discussion

Our results did not support the hypothesis of a predictive or prognostic role of HPI and AUCs calculated by DCE-MRI in liver metastatic CRC patients, thus the primary endpoint of the study was not reached. However, reduced arterial blood flow in metastatic liver can be obtained by chemotherapy alone, without any anti-angiogenic agent; interestingly, HPI and AUC data suggest a possible relationship between tumor metabolism and entire liver perfusion.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics. CA Cancer J Clin 65:87–108CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics. CA Cancer J Clin 65:87–108CrossRefPubMed
2.
Zurück zum Zitat Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259CrossRefPubMedPubMedCentral Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Fong Y, Blumgart LH, Cohen AM (1995) Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin 45(1):50–62CrossRefPubMed Fong Y, Blumgart LH, Cohen AM (1995) Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin 45(1):50–62CrossRefPubMed
4.
Zurück zum Zitat Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27(11):1829–1835CrossRefPubMed Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27(11):1829–1835CrossRefPubMed
5.
Zurück zum Zitat Warren HW, Gallagher H, Hemingway DM, Angerson WJ, Bessent RG, Wotherspoon H et al (1998) Prospective assessment of the hepatic perfusion index in patients with colorectal cancer. Br J Surg 85(12):1708–1712CrossRefPubMed Warren HW, Gallagher H, Hemingway DM, Angerson WJ, Bessent RG, Wotherspoon H et al (1998) Prospective assessment of the hepatic perfusion index in patients with colorectal cancer. Br J Surg 85(12):1708–1712CrossRefPubMed
6.
Zurück zum Zitat Fujishiro T, Shuto K, Hayano K, Satoh A, Kono T, Ohira G et al (2014) Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results. Oncol Rep 31(3):1083–1088PubMedPubMedCentral Fujishiro T, Shuto K, Hayano K, Satoh A, Kono T, Ohira G et al (2014) Preoperative hepatic CT perfusion as an early predictor for the recurrence of esophageal squamous cell carcinoma: initial clinical results. Oncol Rep 31(3):1083–1088PubMedPubMedCentral
7.
Zurück zum Zitat Sarela AI, Gallagher HJ, Macadam RC, O’Riordain DS, Parkin A, Guillou PJ (2000) Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma. Colorectal Dis 2(6):346–350CrossRefPubMed Sarela AI, Gallagher HJ, Macadam RC, O’Riordain DS, Parkin A, Guillou PJ (2000) Abnormal hepatic perfusion index predicts recurrence of colorectal carcinoma. Colorectal Dis 2(6):346–350CrossRefPubMed
8.
Zurück zum Zitat Leen E, Goldberg JA, Angerson WJ, McArdle CS (2000) Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy. Lancet 355(9197):34–37CrossRefPubMed Leen E, Goldberg JA, Angerson WJ, McArdle CS (2000) Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy. Lancet 355(9197):34–37CrossRefPubMed
9.
Zurück zum Zitat White MJ, O’Gorman RL, Charles-Edwards EM, Kane PA, Karani JB, Leach MO et al (2007) Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol 80(950):113–120CrossRefPubMed White MJ, O’Gorman RL, Charles-Edwards EM, Kane PA, Karani JB, Leach MO et al (2007) Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol 80(950):113–120CrossRefPubMed
10.
Zurück zum Zitat Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y (2012) Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 130(10):2359–2365CrossRefPubMed Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y (2012) Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 130(10):2359–2365CrossRefPubMed
11.
Zurück zum Zitat De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J et al (2012) Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 106(12):1926–1933CrossRefPubMedPubMedCentral De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J et al (2012) Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 106(12):1926–1933CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
13.
Zurück zum Zitat White MJ, O’Gorman RL, Charles-Edwards EM, Kane PA, Karani JB, Leach MO et al (2007) Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol 80(950):113–120CrossRefPubMed White MJ, O’Gorman RL, Charles-Edwards EM, Kane PA, Karani JB, Leach MO et al (2007) Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol 80(950):113–120CrossRefPubMed
14.
Zurück zum Zitat Leen E, Angerson WJ, Wotherspoon H, Moule B, Cooke TG, McArdle CS (1995) Comparison of laparotomy, CT, US and DPI in the detection of colorectal liver metastases. Radiology 195:113–116CrossRefPubMed Leen E, Angerson WJ, Wotherspoon H, Moule B, Cooke TG, McArdle CS (1995) Comparison of laparotomy, CT, US and DPI in the detection of colorectal liver metastases. Radiology 195:113–116CrossRefPubMed
15.
Zurück zum Zitat Kunze C, Mentzel HJ, Krishnamurthy R, Fleck R, Stenzel M, Bhargava R et al (2016) Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Invest Radiol 51(1):50–57CrossRefPubMed Kunze C, Mentzel HJ, Krishnamurthy R, Fleck R, Stenzel M, Bhargava R et al (2016) Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Invest Radiol 51(1):50–57CrossRefPubMed
16.
Zurück zum Zitat Totman JJ, O’gorman RL, Kane PA, Karani JB (2005) Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 78(926):105–109CrossRefPubMed Totman JJ, O’gorman RL, Kane PA, Karani JB (2005) Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 78(926):105–109CrossRefPubMed
17.
Zurück zum Zitat Miyazaki K, Collins DJ, Walker-Samuel S, Taylor JN, Padhani AR, Leach MO et al (2008) Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 18:1414–1421CrossRefPubMed Miyazaki K, Collins DJ, Walker-Samuel S, Taylor JN, Padhani AR, Leach MO et al (2008) Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 18:1414–1421CrossRefPubMed
Metadaten
Titel
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy
verfasst von
Marco Tampellini
Dario Gned
Chiara Baratelli
Maria Pia Brizzi
Azzurra Ottone
Irene Alabiso
Chiara Bertaggia
Massimo Di Maio
Giorgio Vittorio Scagliotti
Andrea Veltri
Publikationsdatum
01.12.2016
Verlag
Springer Milan
Erschienen in
La radiologia medica / Ausgabe 12/2016
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-016-0685-7

Weitere Artikel der Ausgabe 12/2016

La radiologia medica 12/2016 Zur Ausgabe

Acknowledgement to Referees

2016 Scientific Referees

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.